Treats megaloblastic anemias due to folic acid deficiency. ANDA 217021, held by Hainan Poly. Leucovorin Calcium.
As of Nov 16, 2026, ANDA 217021 (Leucovorin Calcium), held by Hainan Poly, was first approved by FDA on Jul 10, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 10, 2023 | Original application | Approved | None posted |
| Leucovorin CalciumEQ 50MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin CalciumEQ 100MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin CalciumEQ 200MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin CalciumEQ 500MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
| Leucovorin CalciumEQ 350MG BASE/VIAL · injectable;injection | Leucovorin Calcium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters